Edwards Lifesciences Co. (NYSE:EW) Shares Sold by GraniteShares Advisors LLC

GraniteShares Advisors LLC trimmed its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 7.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,593 shares of the medical research company’s stock after selling 825 shares during the period. GraniteShares Advisors LLC’s holdings in Edwards Lifesciences were worth $808,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of EW. Castleview Partners LLC purchased a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $25,000. Compass Wealth Management LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at about $31,000. Turtle Creek Wealth Advisors LLC acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $34,000. Jackson Grant Investment Advisers Inc. acquired a new position in Edwards Lifesciences during the 3rd quarter worth approximately $38,000. Finally, Janiczek Wealth Management LLC increased its position in Edwards Lifesciences by 108.6% during the 3rd quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company’s stock worth $40,000 after purchasing an additional 303 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Royal Bank of Canada boosted their target price on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research report on Monday. Citigroup upped their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. OTR Global upgraded Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Finally, Stifel Nicolaus upped their target price on Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a research note on Wednesday, February 7th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $91.73.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the sale, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, Director Heisz Leslie Stone sold 7,056 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $86.45, for a total transaction of $609,991.20. Following the transaction, the director now directly owns 26,980 shares in the company, valued at approximately $2,332,421. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock valued at $17,166,254 in the last three months. 1.27% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

NYSE:EW traded up $0.86 during midday trading on Tuesday, hitting $90.06. 2,640,500 shares of the stock were exchanged, compared to its average volume of 3,888,942. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The company has a market capitalization of $54.21 billion, a price-to-earnings ratio of 38.78, a P/E/G ratio of 4.47 and a beta of 1.05. The business has a 50-day moving average price of $90.07 and a two-hundred day moving average price of $77.92. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.64. The company had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The firm’s revenue was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.64 earnings per share. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.